Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading on Wednesday. Stock traders purchased 1,002 put options on the stock. This is an increase of approximately 1,791% compared to the typical volume of 53 put options.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company increased their price objective on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.25.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, Director Gregory T. Lucier bought 48,528 shares of the company’s stock in a transaction on Monday, December 8th. The stock was purchased at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the acquisition, the director owned 155,123 shares of the company’s stock, valued at $569,301.41. The trade was a 45.53% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 2.11% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maravai LifeSciences

A number of large investors have recently bought and sold shares of the stock. Ethic Inc. acquired a new position in Maravai LifeSciences in the second quarter valued at $26,000. Sprott Inc. purchased a new stake in shares of Maravai LifeSciences during the 3rd quarter worth about $29,000. Quantessence Capital LLC acquired a new stake in Maravai LifeSciences during the 3rd quarter worth approximately $31,000. Abel Hall LLC acquired a new position in Maravai LifeSciences during the third quarter valued at approximately $33,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in Maravai LifeSciences during the third quarter worth approximately $33,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Up 1.7%

Shares of NASDAQ:MRVI opened at $2.98 on Thursday. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74. The firm has a market cap of $762.02 million, a price-to-earnings ratio of -3.55 and a beta of 0.39. The stock’s 50-day moving average price is $3.48 and its two-hundred day moving average price is $3.16. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $4.30.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.